Tanvex BioPharma Inc
TWSE:6541
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
36.95
74.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Tanvex BioPharma Inc
Tanvex BioPharma Inc
Additional Paid In Capital
Tanvex BioPharma Inc
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tanvex BioPharma Inc
TWSE:6541
|
Additional Paid In Capital
NT$13.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
SSE:688235
|
Additional Paid In Capital
¥81.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Polaris Group
TWSE:6550
|
Additional Paid In Capital
NT$11.7B
|
CAGR 3-Years
30%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
Tanvex BioPharma Inc
Glance View
Tanvex BioPharma, Inc. operates as clinical stage company, which engages in the research and development, production, and sale of pharmaceutical products. The firm is also engaged in areas of strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing and warehousing, sales and distribution. The Company’s product pipeline includes Neupogen (TX-01), TX-05, TX-04, TX-16, TX-52, and others. The firm offers a vertically integrated manufacturing platform for biopharmaceuticals. By controlling the entire process from research and development (R&D) and cell-line development. The firm is developing and delivering biologic and biosimilar drugs to the people.
See Also
What is Tanvex BioPharma Inc's Additional Paid In Capital?
Additional Paid In Capital
13.6B
TWD
Based on the financial report for Jun 30, 2024, Tanvex BioPharma Inc's Additional Paid In Capital amounts to 13.6B TWD.
What is Tanvex BioPharma Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
13%
Over the last year, the Additional Paid In Capital growth was 9%. The average annual Additional Paid In Capital growth rates for Tanvex BioPharma Inc have been 12% over the past three years , 13% over the past five years .
You don't have any saved screeners yet
